Next 10 |
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first qu...
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significan...
2024-03-25 09:14:50 ET More on Neuronetics Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript Neuronetics: Modest Improvements Are Not Enough Neuronetics announces 5-year exclusive partnership with TCN Neuronetics expects preliminary Q4 revenue to be o...
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and ...
2024-03-07 08:56:49 ET More on Neuronetics Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript Neuronetics: Modest Improvements Are Not Enough Neuronetics expects preliminary Q4 revenue to be over $20M Seeking Alpha’s Quant Rating on Neuronetics ...
MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnershi...
2024-03-05 12:19:09 ET Neuronetics, Inc. (STIM) Q4 2023 Earnings Conference Call March 5, 2024 08:30 a.m. ET Company Participants Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Mark Klausner - Investor Relations ...
2024-03-05 07:34:52 ET More on Neuronetics Neuronetics: Modest Improvements Are Not Enough Neuronetics expects preliminary Q4 revenue to be over $20M Seeking Alpha’s Quant Rating on Neuronetics Historical earnings data for Neuronetics Financial...
MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, wit...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing,...
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first qu...
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significan...